Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia

Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia

OBJECTIVE: To observe the efficacy of polyethylene glycol conjugated asparaginase (peg-asp) for induction treatment of children with newly diagnosed acute lymphoblastic leukemia (ALL)

Détails bibliographiques
Publié dans:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 52(2014), 3 vom: 07. März, Seite 215-7
Auteur principal: Liu, Fang (Auteur)
Autres auteurs: Wan, Yang, Chang, Lixian, Guo, Ye, Yang, Wenyu, Wang, Shuchun, Chen, Xiaojuan, Liu, Tianfeng, Ruan, Min, Zhang, Li, Liu, Xiaoming, Zou, Yao, Chen, Yumei, Zhu, Xiaofan
Format: Article
Langue:Chinese
Publié: 2014
Accès à la collection:Zhonghua er ke za zhi = Chinese journal of pediatrics
Sujets:Journal Article Research Support, Non-U.S. Gov't Antineoplastic Agents Polyethylene Glycols 3WJQ0SDW1A Asparaginase EC 3.5.1.1 Prednisone VB0R961HZT
LEADER 01000caa a22002652 4500
001 NLM238215431
003 DE-627
005 20250217010107.0
007 tu
008 231224s2014 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0794.xml 
035 |a (DE-627)NLM238215431 
035 |a (NLM)24824393 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Liu, Fang  |e verfasserin  |4 aut 
245 1 0 |a Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 30.10.2014 
500 |a Date Revised 02.12.2018 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To observe the efficacy of polyethylene glycol conjugated asparaginase (peg-asp) for induction treatment of children with newly diagnosed acute lymphoblastic leukemia (ALL) 
520 |a METHOD: A total of 268 newly diagnosed children with ALL enrolled in CCLG-2008 from January, 2010 to August, 2012 were analyzed. Patients received either native Escherichia coli asparaginase or pegaspargase along with multiagent chemotherapy during remission induction treatment. Status of bone marrow aspiration was assessed on day 15, day 33 (M1, M2, M3) 
520 |a RESULT: Of the 268 patients stratified, 37.3% (n = 100) were SR, 32.1% (n = 86) were IR, and 31.6% (n = 82) were HR; 159 patients received native Escherichia coli asparaginase and 109 patients received pegaspargase. Characteristics of two groups in age, sex, blood count at diagnosis, immunophenotype and response to prednisolone had no significant difference (P > 0.05). Bone marrow status on day 15 in pegaspargase group was M1 in 70 (64.2%) cases, M2 in 23 (21.1%) and M3 in 16 (14.7%), while in native Escherichia coli asparaginase group, M1 in 112 (70.4%) cases, M2 in 21 (13.2%) and M3 in 26 (16.4%), respectively (χ(2) = 2.938, P = 0.230). Bone marrow status on day 33 was M1 in 105 (96.3%), M2 in 3 (2.8%) and M3 in 1 (0.9%) in pegaspargase group, while it was M1 in 154 (96.9%) cases, M2 in 5 (3.1%) and M3 in native Escherichia coli asparaginase group, respectively (χ(2) = 1.494, P = 0.474) 
520 |a CONCLUSION: Domestic pegaspargase of our country can achieve the similar efficacy in induction treatment for ALL patients as compared with native Escherichia coli asparaginase. The drug could be considered as not only the choice for allergic patients but also a first-line alternative for new patients 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antineoplastic Agents  |2 NLM 
650 7 |a Polyethylene Glycols  |2 NLM 
650 7 |a 3WJQ0SDW1A  |2 NLM 
650 7 |a Asparaginase  |2 NLM 
650 7 |a EC 3.5.1.1  |2 NLM 
650 7 |a Prednisone  |2 NLM 
650 7 |a VB0R961HZT  |2 NLM 
700 1 |a Wan, Yang  |e verfasserin  |4 aut 
700 1 |a Chang, Lixian  |e verfasserin  |4 aut 
700 1 |a Guo, Ye  |e verfasserin  |4 aut 
700 1 |a Yang, Wenyu  |e verfasserin  |4 aut 
700 1 |a Wang, Shuchun  |e verfasserin  |4 aut 
700 1 |a Chen, Xiaojuan  |e verfasserin  |4 aut 
700 1 |a Liu, Tianfeng  |e verfasserin  |4 aut 
700 1 |a Ruan, Min  |e verfasserin  |4 aut 
700 1 |a Zhang, Li  |e verfasserin  |4 aut 
700 1 |a Liu, Xiaoming  |e verfasserin  |4 aut 
700 1 |a Zou, Yao  |e verfasserin  |4 aut 
700 1 |a Chen, Yumei  |e verfasserin  |4 aut 
700 1 |a Zhu, Xiaofan  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 52(2014), 3 vom: 07. März, Seite 215-7  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:52  |g year:2014  |g number:3  |g day:07  |g month:03  |g pages:215-7 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 52  |j 2014  |e 3  |b 07  |c 03  |h 215-7